New lung drug faces off against standard treatment in major trial
Disease control
Not yet recruiting
This study tests a new drug, deupirfenidone, against the current standard treatment pirfenidone for people with idiopathic pulmonary fibrosis (IPF), a lung disease that gets worse over time. About 1,100 adults will take one of the two drugs three times a day for up to three years…
Phase: PHASE3 • Sponsor: PureTech • Aim: Disease control
Last updated May 01, 2026 16:01 UTC